Evaxion's third quarter was less about the income statement than about a strategic retreat to its strongest ground. The company reported a loss of $0.01 per share with no revenue, compared with a profit a year ago that was driven by out-licensing EVX-B3 to MSD. On the Earnings Whispers basis, earnings fell 101.4% year over year and revenue fell 100.0%. There was no consensus estimate to measure against. The real news was management's decision to put internal resources almost exclusively into immuno-oncology. That is the central tension: the scientific case for the AI-Immunology platform keeps improving, while the financial case still depends on share sales rather than the partnership that management has been promising.
The year-over-year swing from a $4.6 million net profit to a $3.5 million net loss overstates any deterioration. Last year's quarter included $7.5 million of license revenue and $2.7 million of finance income tied to the EIB debt settlement. Neither was recurring. Stripped of those items, the business is remarkably steady:
- Quarterly net losses ran $3.6 million, $3.7 million and $3.5 million across the first three quarters of 2026.
- R&D expense fell to $2.3 million from $3.1 million a year ago on reduced headcount.
- G&A held at $1.4 million.
Cost discipline is real. However, steady losses with zero revenue mean the balance sheet is quietly eroding:
- Cash fell from $23.2 million at year-end 2025 to $13.3 million, even after $2.2 million of ATM proceeds.
- Total equity dropped from $17.0 million to $8.1 million.
- The weighted share count rose to 431.9 million from 318.0 million a year earlier.
The call added texture to the pipeline story. EVX-01's three-year Phase 2 follow-up in advanced melanoma, presented at ESMO and SITC, showed sustained T-cell and clinical responses. All six extension patients on EVX-01 monotherapy maintained their responses. Vaccine target precision has climbed steadily, from 81% at year-end 2025 to 86% earlier this year and 89% now. Management described oncology partner interest as "overwhelming." It credited field-level validation, including Moderna/Merck's Phase 3 melanoma data and a positive AML cancer vaccine Phase 3 readout, with lifting the entire personalized-vaccine landscape. The cash runway was nudged from "into the second half of 2027" to "toward the end of 2027." Annual burn is holding near $14 million, and the extension came from ATM sales of $2.2 million in August and $0.8 million in October rather than any operational change.
The strategic pivot cuts both ways:
- **What it adds:** EVX-04 for AML and EVX-05 for glioblastoma with Duke are now the internal priorities. EVX-04 target validation data are due at ASH in December, and the Phase 1 trial application remains on track for year-end. That filing is the only 2026 milestone not yet met, so a slip would break a clean execution record.
- **What it gives up:** The infectious disease programs (EVX-B1, B2, B4 and V1) will advance only if partners fund them, and autoimmune work is limited to completing current validation. The four-pillar platform story management told through the first half has been narrowed. That may be sensible capital allocation, but it is also an admission that the company cannot fund breadth on its own.
Bears have legitimate ammunition here. This was the fourth consecutive call citing "multiple parallel conversations" on partnering with no deal to show for it, and there was no update on Merck. A possible $1.5 million from EIB warrant exercise would help at the margin but does not change the funding picture.
The market has treated the stock harshly despite the data flow. Shares at $2.54 are down 25.3% since the open after the August report and sit 25.9% below the 200-day moving average of $3.43. They peaked at $4.50 on October 21, around the ESMO presentation, and have since given back nearly 44%. The stock entered the report just 4.7% above a fresh 52-week low of $2.43 set the day before. The Earnings Whispers trend signals are mostly negative, with price, sequential growth and AVWAP readings all pointing down. Investor sentiment moved the other way, swinging sharply from slightly negative (-0.05) to a strongly positive reading. That reading registers above the top of the stated -1 to +1 scale, so its exact magnitude should be read cautiously. The direction, however, is unmistakable.
That divergence frames the setup. Investors appear increasingly receptive to the oncology refocus and the EVX-01 durability data, yet the share price reflects persistent concern about dilution and a partnership that keeps failing to materialize. A sentiment rebound sitting on top of a stock near its lows suggests the market wants a concrete deal or clean execution, not more validation awards, before re-rating the shares.
The bottom line is that Evaxion delivered a scientifically encouraging but financially static quarter. Steady losses, a sharper oncology focus and improving EVX-01 data strengthen the platform argument. Shrinking equity, ATM-dependent runway and a still-missing partnering deal keep the burden of proof on management. The EVX-04 filing and ASH data are the near-term tests, but a signed partnership remains the catalyst most likely to change how the market values the company.